To develop disease-modifying therapies for synucleinopathies, it is essential to elucidate how α-synuclein converts to pathologic oligomers and fibrils, which form Lewy bodies in Lewy body disease and GCI in MSA. This evidence concerns the gene SNCA and Lewy body dementia.